Skip to content

Study · Randomized controlled trial · 2006

5 results

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA

The Journal of clinical endocrinology and metabolism13 Dec 2005Cited by 28 (Europe PMC)

PMID16352683 (opens in a new tab)DOI10.1210/jc.2005-1536 (opens in a new tab)PepBankPUB-16352683
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy adults, a single CJC‑1295 injection caused dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more.

    In plain wordsIn healthy adults, one CJC‑1295 injection raised growth hormone levels 2- to 10-fold for 6 days or more, with larger doses giving larger rises.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreasePlasma GH concentration after a single injection
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    four ascending single doses · subcutaneous · 28 d and 49 d trialsAs given in this study (human).

    Measurements

    Mean plasma GH fold increase
    2 to 10 fold
    single injection
    Duration of GH increase
    ≥ 6 d
    single injection

    Source sentences

    Summary
    After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more
    3 context sentences
    Summary · context
    The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.
    Summary · context
    Healthy subjects, ages 21-61 yr, were studied.
    Summary · context
    CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy adults, a single CJC‑1295 injection caused dose-dependent increases in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d.

    In plain wordsIn healthy adults, one CJC‑1295 injection raised IGF-I levels 1.5- to 3-fold for 9 to 11 days, with larger doses giving larger rises.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreasePlasma IGF-I concentration after a single injection
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    four ascending single doses · subcutaneous · 28 d and 49 d trialsAs given in this study (human).

    Measurements

    Mean plasma IGF-I fold increase
    1.5 to 3 fold
    single injection
    Duration of IGF-I increase
    9 to 11 d
    single injection

    Source sentences

    Summary
    After a single injection of CJC-1295, there were dose-dependent increases
    4 context sentences
    Summary · context
    in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d.
    Summary · context
    The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.
    Summary · context
    Healthy subjects, ages 21-61 yr, were studied.
    Summary · context
    CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In healthy adults, the estimated half-life of CJC‑1295 was 5.8-8.1 d.

    In plain wordsIn healthy adults, CJC‑1295 stayed in the body for a long time, with an estimated half-life of 5.8 to 8.1 days.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    Not applicableHalf-life of CJC-1295
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous · 28 d and 49 d trialsAs given in this study (human).

    Measurements

    Half-life
    5.8 to 8.1 d
    CJC-1295

    Source sentences

    Summary
    The estimated half-life of CJC-1295 was 5.8-8.1 d.
    3 context sentences
    Summary · context
    The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.
    Summary · context
    Healthy subjects, ages 21-61 yr, were studied.
    Summary · context
    CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy adults, after multiple CJC‑1295 doses, mean IGF-I levels remained above baseline for up to 28 d.

    In plain wordsIn healthy adults, after several CJC‑1295 doses, IGF-I levels stayed above starting levels for up to 28 days.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    IncreaseIGF-I level after multiple doses
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    two or three weekly or biweekly doses · subcutaneous · 28 d and 49 d trialsAs given in this study (human).

    Measurements

    Duration of IGF-I above baseline
    ≤ 28 d
    multiple doses

    Source sentences

    Summary
    After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d.
    3 context sentences
    Summary · context
    The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.
    Summary · context
    Healthy subjects, ages 21-61 yr, were studied.
    Summary · context
    CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.
  5. 05HumanRandomized controlled trialSafety outcome

    In healthy adults given CJC‑1295, no serious adverse reactions were reported.

    In plain wordsIn healthy adults given CJC‑1295, no serious adverse reactions were reported.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    No significant changeSerious adverse reactions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · 28 d and 49 d trialsAs given in this study (human).

    Source sentences

    Summary
    No serious adverse reactions were reported.
    3 context sentences
    Summary · context
    The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.
    Summary · context
    Healthy subjects, ages 21-61 yr, were studied.
    Summary · context
    CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.